Noxxon Announces Amendment to Loan Agreements
July 16 2018 - 12:00PM
Business Wire
Regulatory News:
NOXXON Pharma N.V. (Paris:ALNOX) (Euronext
Growth Paris: ALNOX), a biotechnology company focused on
improving cancer treatments by targeting the tumor microenvironment
(TME), announced today that it has amended the existing agreements
with Kreos Capital (see 2017 Annual Report for further details)
extending from September 30, 2018 until June 30, 2019, the time
during which Kreos Capital will not request the redemption of and
interest payment on its outstanding debt, and during which
qualifying equity raises will result in conversion of the remaining
debt to ordinary shares of the company.
About NOXXON
NOXXON’s oncology-focused pipeline acts on the tumor
microenvironment (TME) and the cancer immunity cycle by breaking
the tumor protection barrier, blocking tumor repair and exposing
hidden tumor cells. Through neutralizing chemokines in the tumor
microenvironment, NOXXON’s approach works in combination with other
forms of treatment to weaken tumor defenses against the immune
system and enable greater therapeutic impact. Building on extensive
clinical experience and safety data, the lead program NOX-A12 will
deliver top-line data from a Keytruda® combination trial in
metastatic colorectal and pancreatic cancer patients in 2018. The
company plans to initiate further studies with NOX-A12 in brain
cancer in combination with radiotherapy, for which an orphan drug
status has been granted in the US and EU. The company’s second
asset, NOX-E36 is a Phase 2 TME asset targeting the innate immune
system. NOXXON plans to test NOX-E36 in pancreatic cancer patients
both as a monotherapy and in combination. Further information can
be found at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme
Corp.
LinkedIn: https://www.linkedin.com/company/noxxon-pharma-ag
Twitter: https://twitter.com/noxxon_pharma
Disclaimer
Certain statements in this communication contain formulations or
terms referring to the future or future developments, as well as
negations of such formulations or terms, or similar terminology.
These are described as forward-looking statements. In addition, all
information in this communication regarding planned or future
results of business segments, financial indicators, developments of
the financial situation or other financial or statistical data
contains such forward-looking statements. The company cautions
prospective investors not to rely on such forward-looking
statements as certain prognoses of actual future events and
developments. The company is neither responsible nor liable for
updating such information, which only represents the state of
affairs on the day of publication.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180716005540/en/
NOXXON Pharma N.V.Aram Mangasarian, Tel. +49 (0) 30 726
247 0Ph.D., Chief Executive Officeramangasarian@noxxon.comorMC
Services AGRaimund Gabriel, Tel. +49 (0) 89 210228 0Managing
Partnernoxxon@mc-services.euorTrophic CommunicationsGretchen
Schweitzer / Joanne TudoricaTel. +49 (0) 89 2388 7730 / +49 (0) 172
861 8540schweitzer@trophic.euorNewCapAlexia Faure, Tel. +33
(0) 1 44 71 98 51afaure@newcap.fr